About this Research Topic
Despite groundbreaking advances in diabetes care, cardiovascular disease remains a leading cause of death and morbidity in this population. Robust data from large studies demonstrated that type 2 diabetes (T2D) individuals display a 3-fold increased cardiovascular mortality and are susceptible to accelerated progression of atherosclerosis and kidney function impairment. Although the achievement of optimal control of known risk factors has long been considered to play a pivotal role in preventing disability, recent studies indicated that even among optimally controlled patients’ cardiovascular disease manifests earlier and more intensively than in healthy subjects. In this context, attenuating residual cardiovascular risk stands as the next frontier of cardiovascular prevention in T2D.
The goal of this Research Topic is to bring together a collection of papers that individually and collectively addressed the role of new therapeutic targets aimed at attenuating the residual cardiovascular risk of individuals with diabetes. Papers dedicated to investigating the prevention of cardiovascular events in diabetes targeting any of the wide range of deleterious pathways involved in diabetes-related macrovascular complications (eg., endothelial dysfunction, glucose control, cardiac and renal remodeling) are welcome.
We welcome the submission of manuscripts including, but not limited to, the following topics.
Special focus will be given (but is not restricted) to:
• Randomized clinical trials using novel drugs capable of attenuating residual cardiovascular risk of individuals with diabetes.
• Large observational studies aimed at identifying new markers of cardiovascular disease progression in diabetes.
• Experimental studies dedicated to investigating new mechanisms involved diabetes-related vascular complications.
• RCTs or observational studies that evaluate residual cardiovascular risk in diabetes.
The goal of this Research Topic is to bring together a collection of papers that individually and collectively addressed the role of new therapeutic targets aimed at attenuating the residual cardiovascular risk of individuals with diabetes. Papers dedicated to investigating the prevention of cardiovascular events in diabetes targeting any of the wide range of deleterious pathways involved in diabetes-related macrovascular complications (eg., endothelial dysfunction, glucose control, cardiac and renal remodeling) are welcome.
We welcome the submission of manuscripts including, but not limited to, the following topics.
Special focus will be given (but is not restricted) to:
• Randomized clinical trials using novel drugs capable of attenuating residual cardiovascular risk of individuals with diabetes.
• Large observational studies aimed at identifying new markers of cardiovascular disease progression in diabetes.
• Experimental studies dedicated to investigating new mechanisms involved diabetes-related vascular complications.
• RCTs or observational studies that evaluate residual cardiovascular risk in diabetes.
Keywords: Diabetes, Residual Cardiovascular Risk, Atherosclerosis
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
